Human coronaviruses (HCoV) were discovered in the 1960s and were originally thought to cause only mild upper respiratory tract diseases in immunocompetent hosts. This view changed since the beginning of this century, with the 2002 SARS (severe acute respiratory syndrome) epidemic and the 2012 MERS (Middle East respiratory syndrome) outbreak, two zoonotic infections that resulted in mortality rates of approximately 10% and 35%, respectively. Despite the importance of these pathogens, no approved antiviral drugs for the treatment of human coronavirus infections became available. However, remdesivir, a nucleotide analogue prodrug originally developed for the treatment of Ebola virus, was found to inhibit the replication of a wide range of human and animal coronaviruses in vitro and in preclinical studies. It is therefore not surprising that when the highly pathogenic SARS-CoV-2 coronavirus emerged in late 2019 in China, causing global health concern due to the virus strong human-to-human transmission ability, remdesivir was one of the first clinical candidates that received attention. After in vitro studies had shown its antiviral activity against SARS-CoV-2, and a first patient was successfully treated with the drug in the USA, a number of trials on remdesivir were initiated. Several had encouraging results, particularly the ACTT-1 double blind, randomized, and placebo controlled trial that has shown shortening of the time to recovery in hospitalized patients treated with remdesivir. The results of other trials were instead negative. Here, we provide an overview of remdesivir discovery, molecular mechanism of action, and initial and current clinical studies on its efficacy.
Santoro, M.G. (2020). Remdesivir: From Ebola to COVID-19. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.
|Tipologia:||Articolo su rivista|
|Citazione:||Santoro, M.G. (2020). Remdesivir: From Ebola to COVID-19. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.|
|Settore Scientifico Disciplinare:||Settore MED/07|
|Revisione (peer review):||Esperti anonimi|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.bbrc.2020.11.043|
|Stato di pubblicazione:||Online ahead of print|
|Data di pubblicazione:||2020|
|Titolo:||Remdesivir: From Ebola to COVID-19|
|Appare nelle tipologie:||01 - Articolo su rivista|
File in questo prodotto:
|BBRC Santoro MG, Carafoli E 2020 1-s2.0-S0006291X20320878-main-1.pdf||Versione Editoriale (PDF)||Copyright dell'editore||Administrator Richiedi una copia|